KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biocryst Pharmaceuticals (BCRX) Equity Ratio (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Equity Ratio for 9 consecutive years, with 0.94 as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Equity Ratio rose 7.49% year-over-year to 0.94, compared with a TTM value of 0.94 through Mar 2025, up 7.49%, and an annual FY2024 reading of 0.97, down 10.13% over the prior year.
  • Equity Ratio was 0.94 for Q1 2025 at Biocryst Pharmaceuticals, up from 0.97 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.64 in Q1 2023 and bottomed at 1.02 in Q1 2024.
  • Average Equity Ratio over 3 years is 0.88, with a median of 0.94 recorded in 2025.
  • The sharpest move saw Equity Ratio plummeted 58.02% in 2024, then grew 7.49% in 2025.
  • Year by year, Equity Ratio stood at 0.88 in 2023, then fell by 10.13% to 0.97 in 2024, then increased by 2.99% to 0.94 in 2025.
  • Business Quant data shows Equity Ratio for BCRX at 0.94 in Q1 2025, 0.97 in Q4 2024, and 0.95 in Q3 2024.